Answers are grounded in this paper and cite their sources.
Temozolomide (TMZ) remains central to glioblastoma therapy, yet treatment failure reflects both pharmacodynamic resistance and incomplete exposure across relevant intracranial compartments. In this evidence-audited narrative review, we trace TMZ from the systemic circulation across the blood–brain and blood–brain tumor barriers to regional distribution, cellular uptake or export, intracellular retention, chemical activation, and DNA damage. Combined adenosine triphosphate (ATP)-binding cassette subfamily B member 1 (ABCB1)/ATP-binding cassette subfamily G member 2 (ABCG2) deficiency increases brain penetration in mice without changing systemic exposure, supporting a contribution from endothelial transport; however, evidence that individual tumor-cell transporters directly export TMZ is heterogeneous and includes negative findings. Transporter-mediated influx and vesicular partitioning further indicate that inadequate uptake or intracellular removal can be mistaken for classical efflux. Human cerebrospinal fluid and brain-interstitial studies demonstrate partial, compartment-dependent penetration, whereas focused-ultrasound studies support the feasibility of barrier opening. Survival outcomes from single-arm studies cannot be attributed to ultrasound without a randomized comparison. A focused full-text audit of 15 TMZ-containing delivery-platform studies identified extensive formulation and efficacy reporting but only three studies with direct analyte-specific measurements targeting parent TMZ in biological samples. These measurements were limited to plasma or whole blood and single-time-point total-tissue extracts of whole brain or brain tumor; none established regional unbound parent-TMZ pharmacokinetics. We propose a claim–evidence framework that separates direct transport and pharmacokinetic evidence from functional sensitization, association, delivery-concept, and negative evidence. Linking parent-drug exposure, regional distribution, pharmacodynamic competence, safety, and clinical feasibility can help determine when inadequate exposure is a modifiable component of glioma resistance.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: